BMS Praises England’s New HTA Process As Opdualag Gets Funding For Melanoma

England’s health technology assessment body, NICE, and the medicines regulator, the MHRA, are “leading the way” in making innovation available to patients and ensuring an efficient and proportionate use of resources, according to BMS.

Medical Balance Equality
• Source: Shutterstock

Bristol Myers Squibb Company’s melanoma drug Opdualag (nivolumab plus relatlimab) has received a positive reimbursement opinion from England’s health technology assessment (HTA) body, NICE, less than two weeks after the drug was authorized for use by the medicines regulator, the MHRA.

The authorization was granted on 28 December after Opdualag was assessed through the Project Orbis initiative, an international regulatory framework...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet